[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"7026c02a-02d2-4eaf-9842-da3071018ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02443077","created_at":"2021-01-18T11:42:20.749Z","updated_at":"2024-07-02T16:34:37.048Z","phase":"Phase 3","brief_title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02443077","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1","pipe":" | ","alterations":" CD79A mutation + CD79B mutation","tags":["MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 05/10/2025","primary_completion_date":" 05/10/2025","study_txt":" Completion: 05/10/2025","study_completion_date":" 05/10/2025","last_update_posted":"2024-06-07"},{"id":"499207e6-901b-4535-b7c7-217df099a09a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06064344","created_at":"2023-10-03T19:11:19.311Z","updated_at":"2024-07-02T16:35:34.954Z","phase":"","brief_title":"RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma","source_id_and_acronym":"NCT06064344","lead_sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","biomarkers":" BCL2 • CD20 • CCND1 • CD22 • CD5 • CD79A • MME • FCER2","pipe":"","alterations":" ","tags":["BCL2 • CD20 • CCND1 • CD22 • CD5 • CD79A • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 10/07/2023","start_date":" 10/07/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 10/06/2027","study_completion_date":" 10/06/2027","last_update_posted":"2023-10-03"},{"id":"0a498da3-5052-4cfe-b07c-4435fee18fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04668365","created_at":"2021-01-19T20:44:06.435Z","updated_at":"2024-07-02T16:35:47.692Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04668365","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/25/2020","start_date":" 12/25/2020","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-05-18"},{"id":"bcba688d-ccf2-45b4-927a-b48dc238e7e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596097","created_at":"2022-10-27T15:58:27.582Z","updated_at":"2024-07-02T16:36:01.746Z","phase":"Phase 2","brief_title":"Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","source_id_and_acronym":"NCT05596097","lead_sponsor":"LanZhou University","biomarkers":" TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2022-10-27"},{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"}]